Chinese Journal of Tissue Engineering Research ›› 2012, Vol. 16 ›› Issue (32): 6071-6075.doi: 10.3969/j.issn.2095-4344.2012.32.034

Previous Articles     Next Articles

Reinfusion of autologous bone marrow mesenchymal stem cells for treatment of stroke in 30 cases

Chen Wen-ming1, Zou Qing-yan2, Lu Jian-jun1, Hu Yun-xin1, Hu Qiong-li1, Li Zhi-gang1, Zen Zhao-long1   

  1. 1Department of Neurology, Guangdong 999 Brain Hospital, Guangzhou 510510, Guangdong Province, China;
    2Guangzhou Hezu Biotech Co.,Ltd., Guangzhou 510663, Guangdong Province, China
  • Received:2012-01-14 Revised:2012-04-18 Online:2012-08-05 Published:2012-08-05
  • About author:Chen Wen-ming★, Master, Associate chief physician, Department of Neurology, Guangdong 999 Brain Hospital, Guangzhou 510540, Guangdong Province, China wenming6311@tom.com

PDF

476

Abstract:

BACKGROUND: Autologous bone marrow mesenchymal stem cells have certain effects on repairing the neurologic impairment, but there are no well-controlled studies describing autologous bone marrow mesenchymal stem cells for treatment of stroke.
OBJECTIVE: To observe the clinical effects of autologous bone marrow mesenchymal stem cell reinfusion for treatment of stroke.
METHODS: Thirty stroke patients treated by autologous bone marrow mesenchymal stem cells reinfusion were included in the experimental group. Thirty stroke patients who did not receive autologous bone marrow mesenchymal stem cell reinfusion were included in the control group. The National Institutes of Health Stroke Scale (NIHSS) was used to assess the clinical efficacy. At 6 months after treatment, the neurological function recovery and the safety of autologous bone marrow mesenchymal stem cells were investigated.
RESULTS AND CONCLUSION: The NIHSS score decreased significantly in the two groups after 6 months of treatment (P < 0.05). There was significant difference in NIHSS score between before and after treatment (P < 0.05). The NIHSS score of the control group decreased significantly than that of the experimental group (P < 0.05). Autologous bone marrow mesenchymal stem cell reinfusion for treatment of cerebrovascular disease is effective and safe. But this needs to be further confirmed by strictly randomized, double-blinded, controlled clinical studies involving a larger number of samples.

CLC Number: